Medicare’s new drug price negotiation program (MFP) went live January 1st, and community pharmacies are already assessing the real-world impact. While federal officials tout reduced Medicare spending, pharmacy owners are discovering what actually changed and what didn’t.
MFP targets manufacturers. But manufacturers weren’t destabilizing pharmacy finances.
PBMs were and still are.
While certain drug prices have been renegotiated and new reimbursement structures are taking shape, the same intermediaries continue dictating what pharmacies receive and when they receive it. That’s why 2026 is shaping up as another year where independent pharmacies must manage policy shifts without meaningful PBM reform.
Once again, the industry’s smallest, most patient-centered providers are absorbing the financial risk.
Why MFP Doesn’t Address PBM Practices
PBMs Still Control Real-World Reimbursement
MFP adjusted what CMS pays manufacturers, not what PBMs reimburse pharmacies at point of sale.
This means PBMs can still:
- Adjust MAC lists
- Reduce pharmacy reimbursement rates
- Manipulate spread pricing
- Delay payments
They pocket the difference between CMS’s lower acquisition cost and the pharmacy’s contracted rate.
The economics changed upstream, but the mechanism that pressures pharmacies most remains untouched.
Rebate Dynamics Continue Under New Structures
Even with lower list prices on MFP drugs, PBMs still generate revenue through:
- Retained rebates
- “Rebate guarantees”
- Steering toward non-MFP, rebate-generating alternatives
While CMS may spend less, PBMs simply relocate their profit centers. Patients don’t necessarily see lower costs, and pharmacies certainly aren’t seeing stable margins.
Cash Flow Timing Creates New Pressure
Some MFP drugs now operate under refund-based reimbursement, where payment is delayed until plans settle with manufacturers. This timing gap is where independents feel the strain.
Mike Bollinger of Live Oak Bank frames it clearly:
“It’s not if the cash is there, it’s when it’s there. That timing is what creates problems.”
Pharmacies operate on tight, predictable cash cycles. When payers disrupt that rhythm, financial stress accumulates quickly.
Bollinger notes that pharmacies forecast effectively when receivables are consistent. The risk in early 2026 is that MFP reimbursement timing may extend further—creating new cash flow challenges for owners.
What Pharmacies Should Monitor in Early 2026
1. Understand Which MFP Claims Operate Under Which Model
Some MFP drugs now use a refund structure, while others still follow adjusted WAC-based pricing.
Nick Secrest of IPC explains:
“Owners need to understand their mix of IRA drugs impacted by MFP and how the price changes actually work. Some run through WAC shifts, some appear to be moving toward a rebate model. It makes a difference in how the money flows.”
Without clarity on which model applies to each drug, predicting cash flow becomes nearly impossible.
2. Tighten Inventory Management and Avoid Overstocking
January typically brings complexity due to deductible resets, but Q1 2026 may be particularly volatile. Pharmacies should:
- Maintain leaner inventory on MFP drugs
- Avoid carrying excessive on-hand value for items with uncertain reimbursement
- Use shorter ordering cycles for flexibility
The objective is reducing financial exposure while learning how MFP reimbursement actually functions in practice.
3. Monitor Cash Flow Closely Especially Timing
This year isn’t just about profit margins. It’s about payment timing, not just payment amount.
If manufacturer refunds take longer than anticipated to flow through PBMs and plans, pharmacies could face:
- Delayed reimbursements
- Temporary negative margins
- Strain on operating capital
As Bollinger notes:
“Pharmacies run into trouble when they use everyday operating cash to float someone else’s delay.”
Early 2026 requires vigilance and avoiding reliance on operating cash to subsidize unclear reimbursement timing.
4. Medication Synchronization Remains Essential
Med-sync helps control:
- When expensive medications dispense
- When claims process
- How predictable receivables are
With MFP introducing new timing variables, med-sync becomes a cash flow management strategy.
The Larger Issue: MFP May Reduce Medicare Costs, But It Won’t Preserve Pharmacy Access
Here’s what pharmacy owners are recognizing:
MFP didn’t address the problem that’s been constraining community pharmacies for a decade.
MFP may improve Medicare’s budget, but without PBM reform, it risks accelerating closures in the independent pharmacy sector.
The irony:
MFP aims to improve affordability and access but if pharmacies close, access deteriorates.
And PBMs, not pharmacies, created the access problem.
Adapt Efficiently, Stay Engaged
Now that MFP is active, the pharmacies that will navigate Q1 and Q2 successfully will be those that:
- Understand how each MFP drug is reimbursed
- Maintain tight inventory control
- Monitor cash flow timing closely
- Keep med-sync central to workflow
- Secure backup working capital if needed
Owners don’t need to panic, they need to stay agile, informed, and realistic.
And collectively, the industry must continue advocating for PBM reform.
Because while MFP may adjust the economics on paper, PBMs still control the operational reality of pharmacy reimbursement.
Until that changes, community pharmacies will continue doing what they’ve always done: adjust, adapt, and fight to keep serving their patients even when the system works against them.
Author: Robin Rhea, MBA
